Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 12/20 | 0.40 |
| ▸ | EDNRA | P25101 | 12/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.40 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4440829 | 1.00 | EDNRB (0.40) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL570658 | 0.87 | EDNRB (0.50) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL570417 | 0.87 | EDNRB (0.50) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL1067633 | 0.87 | EDNRB (0.50) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL28227186 | 0.86 | EDNRB (0.49) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL28079222 | 0.86 | EDNRB (0.49) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL28079200 | 0.86 | EDNRB (0.49) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL28079191 | 0.86 | EDNRB (0.49) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL4434013 | 0.85 | KMT2A (0.42) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| Valine SCHEMBL17965930 | 0.76 | SLC7A5 (0.44) | EDNRBEDNRANR1I2KCNE1KCNQ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118073-A2 | SELECTIVE ENDOTHELIN TYPE-A ANTAGONISTS | Concert Pharmaceuticals Inc. (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20080262006-A1 | Selective endothelin type-a antagonists | CONCERT PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
| WO-2008097468-A2 | SELECTIVE ENDOTHELIN TYPE-A ANTAGONISTS | CONCERT PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262006-A1 | Selective endothelin type-a antagonists | EDNRA, EDNRB, ECE1 | EDNRB 2/4885EDNRA 1/4885NR1I2 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.